Thymosin Alpha-1
PeptideThe medical score is slightly higher than the community score, as clinical RCTs for specific indications (hepatitis B, sepsis) provide solid evidence [s3, s5], whereas community use is primarily off-label (anti-aging, general immune enhancement) and anecdotal reports are more heterogeneous [c1, c2].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Thymosin Alpha-1 is the best-studied peptide in its class — over 30 clinical trials with more than 11,000 subjects show significant effects in hepatitis B and sepsis, though the large TESTS trial (n=1,106) failed its primary endpoint. Approved in 35+ countries but not in the EU; acquisition in Germany sits in a regulatory grey zone. Community reports of improved immune resilience and energy are mostly positive but rest on a small, uncontrolled base. Subcutaneous injection only — oral formulations marketed by some vendors have no clinical backing.
Description
Synthetic 28-amino acid peptide with immunomodulatory activity; approved in over 35 countries for hepatitis and immunodeficiencies, but not in the EU/Germany [s1, s2].
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue, identical to the natural peptide hormone produced by the thymus gland [s1, s2]. The synthetic version is called thymalfasin and is marketed under the brand name Zadaxin [s10]. The peptide was first sequenced and synthesized in the 1970s by Dr. Allan Goldstein [s1]. It is the most extensively studied member of the thymosin family and has a comprehensive clinical database from more than 30 studies involving over 11,000 subjects [s3]. Primary clinical indications include chronic hepatitis B and C, sepsis, immunodeficiencies, and use as an adjuvant in cancer therapy [s1, s2, s3]. In these areas, Tα1 is approved as a pharmaceutical in over 35 countries, but not in the USA or EU [s10]. With advancing age, thymic activity declines (thymic involution), leading to reduced T-cell production and chronic inflammation. Tα1 is therefore also discussed in the context of anti-aging and longevity, although direct RCT data for healthy older adults are scarce [s4, s8]. In the biohacking context, Tα1 is frequently combined with other peptides such as BPC-157, TB-500, or Epitalon to enhance immune resilience [c1]. However, clinical evidence for such combinations in healthy individuals is limited.
Legal Status (DE)
Thymalfasin (trade name Zadaxin) is approved as a prescription medication in over 35 countries (including for chronic hepatitis B, hepatitis C, and immunodeficiencies), but has been approved neither by the FDA nor by the EMA for the European market. In Germany, thymalfasin holds no marketing authorization as a medicinal product from the BfArM and is not marketable as a dietary supplement. Possession and acquisition for research purposes exists in a regulatory gray area; legal prescription by a German physician is currently not possible [s1, s10].
Mechanism of Action
Thymosin Alpha-1 exerts its effects through multiple immunological signaling pathways [s1, s2]: 1. T-cell maturation and differentiation: Tα1 promotes the maturation of T-precursor cells in the thymus into functional CD4+ and CD8+ T-cells. It activates Toll-like receptors (TLR2 and TLR9) on dendritic cells and macrophages [s2, s9]. 2. Cytokine modulation: Tα1 stimulates production of Th1 cytokines (IFN-γ, IL-2) and promotes a cellular immune response, while dampening excessive inflammatory reactions [s1, s2]. 3. NK cell activation: Natural killer cells are activated by Tα1, contributing to antiviral and antitumoral immune surveillance [s2]. 4. Antioxidant activity: According to a recent review, Tα1 possesses antioxidant properties that may contribute to the reduction of oxidative stress [s8]. 5. Tumor immunology: In cancer models, Tα1 inhibits the STAT3-MMP2 signaling cascade in PD-L1-high-expressing tumor cells and may potentiate the efficacy of immune checkpoint inhibitors (anti-PD-1) [s6, s7]. 6. Vaccine adjuvant effect: In clinical trials, Tα1 enhanced the immune response to vaccines (geometric mean titer higher than in the placebo group) [s3]. The half-life of Tα1 following subcutaneous injection is approximately 2 hours; biological effects persist considerably longer [s1].
Dosing
Chronische Hepatitis B / Immundefizienzen (klinisch)
- Dose
- 1.6 mg
- Frequency
- 2× wöchentlich subkutan
- Route
- injektion-subkutan
- Duration
- 6–12 Monate
- Timing
- Fixed days of the week (e.g. Monday and Thursday)
- With food
- optional
Allgemeine Immunmodulation / Biohacking (off-label)
- Dose
- 0.5–1.6 mg
- Frequency
- 1–2× wöchentlich subkutan
- Route
- injektion-subkutan
- Duration
- 4–12 Wochen
- Timing
- Morning on an empty stomach or as directed by physician
- With food
- optional
Sepsis-Adjuvanz (klinisch, stationär)
- Dose
- 1.6 mg
- Frequency
- täglich subkutan für 7 Tage, dann 2× wöchentlich
- Route
- injektion-subkutan
- Duration
- Bis zu 28 Tage
- Timing
- Under inpatient monitoring
- With food
- optional
In clinical studies, doses of up to 16 mg twice daily over 4 weeks were reported without significant adverse effects [s10]. The standard dose for approved indications is 1.6 mg subcutaneously twice weekly. Higher doses outside of controlled trials are not recommended.
Thymosin Alpha-1 is administered exclusively by subcutaneous injection; oral bioavailability has not been established [s1]. Some vendors market oral drop formulations whose clinical efficacy is not supported by RCTs [s2]. Use outside of clinical trials in Germany does not fall within any approved indication.
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Reaktionen an der Injektionsstelle (Schmerzen, Brennen, Juckreiz) Most frequently reported adverse effect in clinical trials; symptoms last less than 30 minutes [s10, s12]. | gelegentlich | leicht |
| Fieber Documented as a mild to moderate adverse effect in clinical trials [s12]. | gelegentlich | leicht |
| Übelkeit Reported in clinical studies as a mild to moderate adverse effect [s12]. | gelegentlich | leicht |
| Grippeähnliche Symptome (Myalgie, Müdigkeit) Occasionally described in clinical trials; likely immunostimulatory effect [s12]. | gelegentlich | leicht |
| Überreizung des Immunsystems / Autoimmunphänomene Theoretically possible in patients with autoimmune diseases due to T-cell-stimulating activity; not documented in large studies [s1, s2]. | theoretisch | moderat |
| Hypersensibilitätsreaktion / Anaphylaxie Contraindicated in known hypersensitivity to thymalfasin or excipients [s10]. | selten | schwer |
Contraindications
Absolute contraindication per Zadaxin summary of product characteristics; hypersensitivity reactions are possible [s10].
Tα1 stimulates T-cell activity; theoretical risk of exacerbating autoimmune processes. Insufficient safety data for this population [s1, s2].
Immunostimulatory effects may interfere with immunosuppressants and increase the risk of rejection [s1].
Insufficient safety data available for pregnancy and lactation; use not recommended [s10].
Interactions
Synergistic
Tα1 may potentiate the efficacy of checkpoint inhibitors in preclinical melanoma models; combination in metastatic melanoma has been clinically investigated [s6, s7].
Meta-analysis demonstrates superiority of the entecavir + Tα1 combination over entecavir monotherapy in HBV cirrhosis [s13].
Tα1 increased geometric mean antibody titers post-vaccination in clinical studies; adjuvant effect established [s3].
Thymosin Alpha-1 modulates immune activity and supports T-cell function, while KPV inhibits inflammatory signaling pathways and promotes tissue repair. Together they form a complementary strategy for restoring immunological balance.
Thymosin Alpha-1 enhances immunomodulation and defense against infection, while epitalon, as a telomerase activator, supports cellular renewal, sleep regulation, and longevity mechanisms. This combination is used as an anti-aging and immune resilience stack.
Thymosin Alpha-1 modulates the immune response and T-cell activity, while BPC-157 promotes tissue repair and angiogenesis. The combination is considered particularly effective for injury recovery with concurrent immune support.
Caution
Antagonistic interaction possible; Tα1 may attenuate the immunosuppressive effect [s1].
Combination therapies are practiced in the biohacking community; immune system overload or redundancy possible; no clinical data on combination safety [c1].
Studies
Tier A — High Evidence
Community Evidence
Top reported benefits
- Improved immune resilience and fewer infections
- More energy and faster recovery after illness
- Positive experiences in combination with BPC-157 and TB-500
- Subjective improvement in chronic inflammatory conditions
Top reported issues
- Initial 'detox reaction' after first injections (fatigue, mild fever)
- Uncertainty about quality and purity of supply sources
- High cost compared to other peptides
- Lack of clarity on optimal dosing protocol
Many users report sourcing from gray markets without quality control. The "detox reaction" upon first use is widespread and it remains unclear whether it is immunostimulatory or nonspecific. The German-speaking community is small; most anecdotal reports originate from English-language forums [c1, c2]. Combination with numerous other peptides (Thymalin, Epitalon, KPV) without clinical evidence for the safety of such stacks [c1].
Scientific Sources
- Thymosin alpha 1: Biological activities, applications and potential uses
Romani L, Bistoni F, Montagnoli C, et al. (2020). Frontiers in Immunology (PMC7115394)BPMID:32265929DOI - Zadaxin (Thymalfasin): Side Effects, Uses, Dosage, Interactions, Warnings
RxList Medical Editorial Team (2024). RxList / WebMDBLink - The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression
Pham T, et al. (2023). InflammopharmacologyADOI - Thymalfasin bei COVID-19 — klinische Studienbeschreibung NCT04487444 / NCT04428008
ICH GCP / ClinicalTrials.gov (2021). ClinicalTrials.gov / ICH GCPBLink - The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis
Hu X, et al. (2020). PubMed / NCBIAPMID:33076834 - Thymosin alpha 1: A comprehensive review of the literature
Goldstein AL, Garaci E, Tuthill C, et al. (2020). International Immunopharmacology (PMC7747025)BPMID:33229079DOI - Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Dinetz E, et al. (2024). Alternative Therapies in Health and MedicineBPMID:38308608 - The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Wu J, Zhou L, Liu J, et al. (2025). The BMJADOI - Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials
Zhu X, et al. (2025). Frontiers in Cellular and Infection MicrobiologyADOI - The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets
Belardelli F, Ferrantini M, Proietti E, et al. (2025). PMC12433645BLink - A Reappraisal of Thymosin Alpha1 in Cancer Therapy
Moroni M, Schiavoni G, Mattei F, et al. (2019). Frontiers in Oncology (PMC6742685)BPMID:31552186DOI - Aging and Thymosin Alpha-1
Sorrenti V, et al. (2025). International Journal of Molecular SciencesBDOI - Thymosin Alpha-1 Research Guide — TLR2/TLR9 Immune Modulation, 35+ Country Approval & 11,000+ Subject RCT Database
YourPeptideBrand Editorial Team (2026). yourpeptidebrand.com (Industrie-Quelle)CLink
Community Sources
Storage
Unopened
Lyophilized powder: store at 2–8°C (refrigerator); protect from light. Follow manufacturer instructions.
Opened
After reconstitution with bacteriostatic water: store at 2–8°C; use within 30 days. Do not freeze.
Notes
Do not shake reconstituted solution. Inspect for turbidity or particulates prior to injection [s1].